vTv Therapeutics reports $19.2 million net loss in FY 2022 ahead of Phase 3 trials of Type 1 …
As it prepares for Phase 3 trials for diabetes treatment, … an oral treatment for Type 1 Diabetes – heading into Phase 3 clinical trials.
As it prepares for Phase 3 trials for diabetes treatment, … an oral treatment for Type 1 Diabetes – heading into Phase 3 clinical trials.
